Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (41-50 of 221) with videos related to

Pageof 23
Sort By:
Anti-Cancer Drugs|November 29, 2007
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2Afshin Dowlati, Amy Kluge, David Nethery, et al.
The Oncologist|May 4, 2017
DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant EntityEnrico Castellucci, Tianfang He, D Yitzchak Goldstein, et al.
Oncotarget|December 18, 2010
EGFR-mutated lung cancer: a paradigm of molecular oncologyZhenfeng Zhang, Amy L Stiegler, Titus J Boggon, et al.
Current Oncology Reports|July 13, 2010
Molecular testing in lung cancer: the time is nowHaiying Cheng, Xunhai Xu, Daniel B Costa, et al.
Clinical Lung Cancer|September 21, 2024
Untapping the Prognostic Value of Patient-Generated Health Data in Locally Advanced Non-small Cell Lung CancerNitin Ohri, William Bodner, Madhur Garg, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2021
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparisonBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Expert Review of Respiratory Medicine|March 11, 2016
Recent advances in the management of pulmonary sarcomatoid carcinomaElaine Shum, Matthew Stuart, Alain Borczuk, et al.
Clinical and Translational Radiation Oncology|June 22, 2023
Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancerMichael Pennock, Balazs Halmos, William Bodner, et al.
Vaccines|October 27, 2022
Prevalence and Assessment of Factors Associated with COVID-19 Vaccine Hesitancy in an Ethnic Minority Oncology Patient PopulationMatthew Lee, Emily Miao, Bruce Rapkin, et al.
Respiration; International Review of Thoracic Diseases|November 29, 2016
The Evolving Role of Biomarkers in Personalized Lung Cancer TherapyJanaki Sharma, Elaine Shum, Vincent Chau, et al.
Pageof 23

Showing results (41-50 of 221) with videos related to

Sort By:
Pageof 23
Anti-Cancer Drugs|November 29, 2007
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2Afshin Dowlati, Amy Kluge, David Nethery, et al.
The Oncologist|May 4, 2017
DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant EntityEnrico Castellucci, Tianfang He, D Yitzchak Goldstein, et al.
Oncotarget|December 18, 2010
EGFR-mutated lung cancer: a paradigm of molecular oncologyZhenfeng Zhang, Amy L Stiegler, Titus J Boggon, et al.
Current Oncology Reports|July 13, 2010
Molecular testing in lung cancer: the time is nowHaiying Cheng, Xunhai Xu, Daniel B Costa, et al.
Clinical Lung Cancer|September 21, 2024
Untapping the Prognostic Value of Patient-Generated Health Data in Locally Advanced Non-small Cell Lung CancerNitin Ohri, William Bodner, Madhur Garg, et al.
Lung Cancer (Amsterdam, Netherlands)|April 11, 2021
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparisonBalazs Halmos, Thomas Burke, Chrysostomos Kalyvas, et al.
Expert Review of Respiratory Medicine|March 11, 2016
Recent advances in the management of pulmonary sarcomatoid carcinomaElaine Shum, Matthew Stuart, Alain Borczuk, et al.
Clinical and Translational Radiation Oncology|June 22, 2023
Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancerMichael Pennock, Balazs Halmos, William Bodner, et al.
Vaccines|October 27, 2022
Prevalence and Assessment of Factors Associated with COVID-19 Vaccine Hesitancy in an Ethnic Minority Oncology Patient PopulationMatthew Lee, Emily Miao, Bruce Rapkin, et al.
Respiration; International Review of Thoracic Diseases|November 29, 2016
The Evolving Role of Biomarkers in Personalized Lung Cancer TherapyJanaki Sharma, Elaine Shum, Vincent Chau, et al.
Pageof 23